Sumitomo ups ante and wins support for Myovant takeover

A sweetened offer from Sumitomo Pharma has convinced endocrinology specialist Myovant to agree to a takeover, after its first was rejected.

Exscientia starts trials of AI-designed Alzheimer's drug

Exscientia has advanced a drug candidate for Alzheimer's disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discov

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Sumitomo Dainippon bolts on pipeline via $3bn Roivant allian...